Insights

Washington – August 20, 2026: The Best Lawyers in America® has recognized 57 of the firm's attorneys in its 2027 edition, a testament to the firm's deep bench of legal talent across practices and offices nationwide. In addition, 29 attorneys have been named to the Best Lawyers: Ones to Watch® list, recognizing outstanding attorneys earlier in their careers. 

Washington, D.C. – July 22, 2026 – Crowell & Moring LLP today shared results from its firmwide integration of Legora as a collaborative AI platform. Crowell has realized significant gains in opportunities to deliver for clients across practices and jurisdictions.  

Washington – June 10, 2026: Crowell & Moring has been recommended in eight practice areas in the 19th edition of the Legal 500 United States. In addition, partner Daniel Forman, co-chair of the firm’s Government Contracts Group, has been named to the Legal 500’s “Hall of Fame” for Government Contracts, and partner David (Dj) Wolff, co-chair of the firm’s International Trade Group, has been named a “Leading Partner” in International Trade and National Security.

Enbrel (etanercept) is one of the best-selling biologic drugs in the United States, approved to treat rheumatoid arthritis and other serious inflammatory conditions. Etanercept was launched as Enbrel in 1998 as a treatment for moderate to severe rheumatoid arthritis, and was later approved to treat additional inflammatory diseases including plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and polyarticular juvenile idiopathic arthritis.  

If a court finds that a patent applicant intentionally misrepresented or withheld material information from the USPTO with the intent to deceive, the consequences are severe, leading to unenforceability of the entire patent (and likely any later patents claiming priority to the unenforceable patent).

The first applications to lift an automatic suspension under the Procurement Act 2023 (the Act) have recently been decided. In Parkingeye Limited v Velindre University NHS Trust & Anor [2026] EWHC 1019 (TCC), handed down on 1 May 2026, HHJ Keyser KC dismissed applications by two NHS contracting authorities to lift the suspension preventing them from concluding a car park management services contract. This is the first judicial consideration of the new test under section 102(2) of the Act.

Because of recent changes to Federal and State law regulations, companies that manufacture, import, sell, or distribute products or equipment with components that contain certain “PFAS” materials face imminent and overlapping compliance obligations. This webinar will provide actionable information companies can use to determine whether they are impacted by these State and Federal requirements as well as practical advice for complying with these obligations. Topics that will be covered include the following:

The landscape of AI governance and regulation is shifting. Following the release of the White House’s “America’s AI Action Plan” in July 2025 and the President’s signing of related Executive Orders, the White House has emphasized (at least rhetorically) a preference for innovation, adoption, and deregulation. But that does not tell the entire story. The Administration remains committed to exercising a heavy hand in AI, including by banning the U.S. government’s procurement of so-called “woke AI,” intervening in the development of data centers and the export of the AI technology stack, imposing an export fee for certain semiconductors to China, and assuming a stake in a U.S. semiconductor company. State legislatures are also racing to implement their own regulations, particularly around AI’s use in critical areas, such as healthcare, labor and employment, and data privacy. The many sources of regulation raise the specter of a fragmented compliance environment for businesses. This webinar will delve into the Administration’s AI strategy, going beyond the headlines to analyze:

On October 16, 2025, Partner Matthew F. Ferraro, Partner and CHS Managing Director Jason Johnson, and Counsels Jacob Canter and Anna Z. Saber hosted a webinar on the shifting dimensions of AI governance and regulation. They discussed federal policy, state laws, international efforts, and key court cases and how these many sources of regulation serve to fragment the AI compliance environment for businesses and how firms can respond. Click here to view the webinar on demand.